Are you doing agriculture business in India?

Bizbilla is the best b2b portal in the world where agriculture business people can post their business for free and get wide range of exposure locally and globally.

By posting their business in bizbilla they can get unique recognition and global online presence in major search engines that helps them to lift their business into the digital world.By joining as a free member the business person can get free business website,B2B app , Business directories and so on.

In this agriculture b2b portal bizbilla.com you can post your business products,services,sell offers,buying needs, and trade shows for free and get connected with worldwide business people. you can also build your own website for free and showcase your products to promote it worldwide.

Make your agriculture business handy with Bizbilla b2b android app.you can do and manage your business with your mobile by installing and using the android app.

The Agriculture b2b marketplace allow you to post your agriculture business and b2b classifieds along with your respective city and country wise. It will helps to get your business to the next level.

India's First Green Rail Corridor Launched In Tamil Nadu

The nation's first Green Rail Corridor, a 114-km long Rameswaram-Manamadurai stretch in Tamil Nadu which ensures zero toilet discharge on rail tracks, was today inaugurated by Railways Minister Suresh Prabhu.
    
Trains in the section have been equipped with bio-toilets ensuring zero discharge of human waste on the rail tracks.
    
Inaugurating the corridor through video-conferencing from here, Mr Prabhu said his ministry was committed to converting all toilets in railways to bio-toilets.

   
He said till March 2016, a total of 35,104 bio-toilets had been provided and since then till last week 7,000 more new bio-toilets have been made operational.
    
"During 2016-17, our target is to provide 30,000 new bio-toilets and the benefits are obvious," he said adding the initiative will also bring down maintenance cost significantly. "Before end of March next year, the line to (from Jammu) Katra will also be human waste free," he said.
     
He also inaugurated high speed upgraded Wi-Fi facility, set up in association with Google, at Chennai Central Railway Station and a similar facility at Tiruchirappalli through video conferencing.  The Wi-Fi amenities were part of the digital India plan of Prime Minister Narendra Modi, he said.
     
He launched a traditional medicine centre under Ayush at Perambur Railway Hospital here, a broad gauge line between Thiruvallur and Thiruvalangadu stations on the Chennai-Arakkonam line.
     
On developing rail infrastructure, he said the Tamil Nadu government should go for a Joint Venture with Railways like other southern States. "I know we want to do more for Tamil Nadu. And for that, I had requested (Chief Minister) Jayalalithaa, one of the great leaders of the state and India, madam ji to join hands with us so that we can have a JV for development," he said.
     
The Minister said he had written to Jayalalithaa only a few days ago on the matter. He said Tamil Nadu's neighbouring states of Kerala, Andhra Pradesh, Telangana and Karnataka, had agreed for JV with the Railways. "So, we are awaiting a response from your state," he said hailing Jayalalithaa as "dynamic."
     
Referring to high speed network plans, he cited increasing speed of trains from 110 to 160 kmph in the Chennai-Bengaluru sector, and between New Delhi and Chennai.
    
"The idea is that we should try to bring in high speed network to all the people of India which will help bring in a complete transformation."
     
To develop the high speed network, work was on to devise strategies, one of which was using Talgo coaches and a trial with 180 kmph speed run with full load had been completed.
    
"Completion of trial between Mumbai and Delhi (will happen) in the next few days. If it is successful, it has been successful so far, then we will ask them to manufacture in India under PM's Make in India programme," Mr Prabhu said.

Source <> http://www.ndtv.com/tamil-nadu-news/indias-first-green-rail-corridor-launched-in-tamil-nadu-1435571

Image Source <> http://economictimes.indiatimes.com/photo/52173031.cms

Inflation in India

This festival Season rising prices for some food and firm demand probably pushed up India's retail inflation in October for the third straight month, making it less likely the central bank will cut interest rates at its policy review next month.

Retail inflation in India has slowed sharply, but a surge in prices of items like lentils threaten the popularity of Prime Minister Narendra Modi, whose party lost elections in India's third-most populous state on Sunday.

Higher demand for consumer durables and food items during the festival season beginning in October also contributed to inflation.

Analysts said inflation may moderate once festival demand softens and prices of lentils and vegetables fall as imports increase.

"The uptick in inflation, if any, related to the festive demand, would dissipate over the next month," said Aditi Nayar, an economist at ICRA, the Indian arm of Rating Agency Moody's.

She said easing prices of pulses would also soften headline inflation to some extent.

Food items, which accounts for almost half the CPI basket, have increased in price up to one-third, forcing the government to import pulses and onions to offset the impact of a drought for the second straight year in much of the country.

Consumer prices INCPIY=ECI likely rose 4.82 percent in October from a year earlier, according to a Reuters poll of economists, compared with September's 4.41 percent.

Industrial output INIP=ECI, however, likely slowed to 4.7 percent in September compared with a year earlier and from a 6.4 percent rise in the previous month.

Both sets of data will be released around 1200 GMT on Thursday.

Raghuram Rajan the governor of the Reserve Bank of India, has said the central bank expected to meet its 6 percent retail inflation target for January and will focus on its 5 percent target for March 2017.

He cut the benchmark policy rate by a half percentage point to 6.75 percent in September, after months of pleading by government leaders and industrial groups.

Analysts said that the central bank may leave rates unchanged in its policy review meeting in early December and might wait for the US Fed decision on interest rates.

"A rate cut in the December policy remains a remote possibility, partly in light of the looming interest rate hike by the US Federal Reserve," Nayar said.


Source Link :<> http://timesofindia.indiatimes.com/business/india-business/Indias-higher-food-prices-seen-pushing-retail-inflation-in-October/articleshow/49755140.cms

Coffee Day stocks make weak debut on bourses

Coffee Day Enterprises shares, operator of India's biggest coffee chain, opened at Rs 317 on NSE, below its initial public offering price of Rs 328 on its market debut on Monday.

Coffee Day Enterprises shares, operator of India’s biggest coffee chain, opened at Rs 317 on NSE, below its initial public offering price of Rs 328 on its market debut on Monday. On BSE, shares of Coffee Day Enterprises opened at Rs 313.

At 10.08 am, Coffee Day Enterprises shares were trading at Rs 292.75 apiece. The scrip touched a high and low of Rs 318 and Rs 280.70, respectively, on BSE in trade so far.

Coffee Day had raised Rs 1,150 crore in the country’s second biggest IPO this year after Interglobe Aviation, parent company of the IndiGo airline.

The company’s Rs 1,150-crore initial public offering (IPO) was the biggest in nearly three years when it hit the market, but now it has been overtaken by Indigo’s Rs 3,018 crore IPO.

Coffee Day Enterprises had fixed the issue price at Rs 328 per share for investors. The IPO, which was opened for subscription during October 14-16, was subscribed 1.64 times at price band of Rs 316-328 a share.

Coffee Day Enterprises had raised over Rs 334 crore from anchor investors ahead of the IPO, while in March, the firm had mobilised Rs 100 crore in a pre-IPO funding from Nandan Nilekani and Rare Enterprises (owned by Rakesh Jhunjhunwala and Ramesh Damani), among others.

Source Link: <> http://www.financialexpress.com/article/markets/indian-markets/coffee-day-share-price-on-sensex-nifty-on-nov-2-2015/159876/

OnePlus to manufacture smartphones in India, teams up with Foxconn

OnePlus is among the latest companies to join the Indian government’s ‘Make in India’ initiative. At an event in Bangalore today, the company announced its partnership with Foxconn to manufacture smartphones in India.

OnePlus’ smartphones will be manufactured at Foxconn’s Rising Stars factory within the Sri City Integrated Business City in Andhra Pradesh. This facility will be able to produce up to 500,000 handsets per month. OnePlus says that the first batch of its made in India handsets will be commercially available by the end of 2015.

“Producing smartphones in India is one of the most important decisions that we have made so far at OnePlus, and we are thankful to the Government of Andhra Pradesh and Foxconn for helping us make this happen,” Pete Lau, Founder & CEO, OnePlus said. “India being one of our biggest markets worldwide, we are committed to a long term sustainable growth path. This move will strengthen our presence and help us step up momentum in India.”

At the event, OnePlus also revealed some numbers saying that it has so far sold 250,000 OnePlus One units in India since its launch last year. On the global scale, the company has sold over 1.5 million OnePlus One handsets since last year. Going forward, the company aims at selling a million smartphones in India by the end of 2015.

Since the launch of the OnePlus 2 in August this year, the smartphone was up for sale without the need for invites today on Amazon India. The company said that in the sale that lasted an hour, it sold 15,000 handsets. The company also announced that it plans on conducting another open sale tomorrow at 8:00AM on the e-commerce site.

As mentioned above, OnePlus is one of the latest companies to announce its plans for smartphone manufacturing in India. Lenovo and Motorola will be manufacturing smartphones at their Sriperambudur plant in Chennai, while Asus India’s Peter Chang recently said, “Asus is looking at manufacturing smartphones in India via contract manufacturers.”

Xiaomi, on the other hand, launched the Redmi 2 Prime, its first ‘made in India’ smartphone. The Chinese company partnered Foxconn, which has set up a manufacturing facility in Sri City in Andhra Pradesh. Other companies that have shown a similar interest include the likes Huawei, Oppo, and Microsoft too is reported to have approached Foxconn to manufacture its Lumia smartphones in the country.

Gionee today is hosting an event in India, where it too will announce its first smartphone that will be manufactured in India.

Source Link :<> http://www.bgr.in/news/oneplus-to-manufacture-smartphones-in-india-teams-up-with-foxconn/

Waive interstate transmission charges for electricity

Mr. Piyush Goyal, Minister for New and Renewable Energy, announced last week that the government plans to waive interstate transmission charges for electricity generated by renewable sources . This waiver was earlier included in the proposed amendments to the country’s existing tariff policy of 2005 , but the amendments are yet to be approved. However, for speedy promotion of renewable energy projects, the central government is actively moving to implement amendments such as the waiver of interstate transmission charges that are under its control.

To meet the 60 GW of utility scale solar target, interstate power transmission is essential and needs to be encouraged.

Waiver of interstate transmission charges will allow developers to install solar projects in states with cheaper land and higher irradiation.

The grid infrastructure will need to be strengthened to evacuate power. Waiver of transmission charges is a positive short term support for the sector but it is more important to make the necessary investment commercially viable for sustainable growth of the sector.

At present, solar projects are usually developed close to consumption centres within the same state. If the interstate transmission charges are waived, greater number of solar projects will be installed in states which are providing better economics to project developers, leading to higher concentration of solar projects in those select states in India, for example, Rajasthan, Gujarat, Madhya Pradesh, Andhra Pradesh and Telangana. 

However, these states cannot necessarily absorb the higher capacity of intermittent power in local load centres. The role of interstate transmission of power will thus become crucial as the penetration increases. The incentive in the form of free transmission of power will therefore provide a major boost to the solar sector.

A good example of the benefit of this waiver will be solar power procurement for the state of Delhi. Land in Delhi is expensive and scarcely available. The power distribution companies of Delhi plan to buy solar power from projects set up in states such as Madhya Pradesh and Rajasthan. Waiver of transmission charges could result in lowering of solar power tariff by up to 10%.

Obviously, free transmission is a positive move for the sector but this policy should be seen only as a short term incentive. The inter-state transmission corridors need massive investment, estimated at INR 430 bn covering the states of Tamil Nadu, Karnataka, Andhra Pradesh, Gujarat, Maharashtra, Rajasthan, Himachal Pradesh and Jammu & Kashmir (refer). This investment needs to be commercially viable to make the long-term prospects of solar energy sustainable.

Source<> http://www.bridgetoindia.com/blog/waiver-of-interstate-transmission-charges-will-boost-solar-but-only-in-the-short-term/#show-comments

Pharma Contract Manufacturing On The Rise In India.

The past few decades have been very productive for India, as it took a major leap from pharmaceutical production, to include contract manufacturing.

According to the president of the Indian Drug Manufacturers' Association (IDMA), S V Veerramani, the overall pharma contract manufacturing industry is growing at 20%, providing a burgeoning opportunity for small and medium enterprises, reports Brand India Pharma. The current market value is estimated at 50% of the domestic production, which roughly translates to $5.3 billion. Multinationals hold a generous 20%-25% stake in the domestic pharmaceutical market.

For the basic manufacture of medical products and drugs, India has a far superior edge over nations such as China, Vietnam and Ireland, due to resources including manpower, technically knowledgeable work force, and World Health Organization-Good Manufacturing Practice- approved production premises. A substantial 40% lower cost of operation and production is clearly the highlight for multinationals to consider India for their outsourcing needs.

Waiver to Phase III studies of certain drugs in India an incentive:

With the advent of multinational pharmaceutical organizations, and their rapidly growing presence in the country, the concept of contract manufacturing has steadily evolved and quickly adapted, so as to encompass services such as basic manufacturing of medicinal products, formulation development, stability studies, and various stages of clinical trials. 

In addition, scale-up of drug syntheses, and late clinical trial studies have also been profitable protocols in this sphere. The Drug Technical Advisory Board (DTAB) has agreed to grant a waiver to Phase III studies of certain drugs in India, which are from the regulated markets of the USA and European Union. This step is an incentive for many pharmaceutical organizations to focus on India, as the cost savings could be enormous. 

Also it is estimated that patented drugs worth $85 billion in potential annual sales in the USA would be off patent during the period 2014-2020. Price competitiveness and manufacture of these generic drugs in the most cost efficient manner would be the key drivers boosting the prospects of the Indian players as India is known to have the world's best known low-cost manufacturing centers, with the highest number of US Food and Drug Administration (USFDA) approved manufacturing plants outside the US. 

The government is also looking at incentivizing the upgradation of Schedule M facilities to WHO GMP complaint units with the help of soft loans, which would lead to additional 1000 units being certified WHO-GMP compliant, further corroborating the manufacturing processes.

MNCs outsourcing to Indian producers:

P V Appaji, director general of Pharmexcil, India’s Pharmaceutical Export Promotion Council, mentioned that multinational companies in India have stopped manufacturing some of their products and have outsourced to Indian manufacturers. Products which are even brand leaders in its segments are also outsourced to many Indian companies and yet could retain its market share. 

The rising cost of manufacturing and some of the aging plants of Europe reaching their life cycle conclusion may open up enormous opportunities to India's companies in contract manufacturing as European companies are also considering to either relocate those units in cost efficient centres like India or to outsource to India manufacturers. 

Beside, over the last five years or even more the innovative products introduced do not command vary large market value and are not blockbusters as they used to be earlier. Research pipelines, though now getting moderately filled, may have only moderate advantage over the existing products and hence very few of them may go on to become real blockbusters. Hence MNCs are now adopting the strategy of marketing the brand even after the product goes off patent by slashing down their brand's price to the level of generics. 

Therefore, to get the maximum mileage of their brands, they are looking to outsource their manufacturing to more cost efficient, centres, like India and yet retain their quality and brand image. This is a newer opportunity of contract manufacturing opening up.

This trend is on the rise in the domestic market and India is making an appropriate move by inviting Japan's pharma industry to locate their units in India either wholly-owned or in joint partnership with India companies. Japan's companies are considering India's offer with keen interest. "Our idea is to promote Indian generics in the international markets. Around 20 Japanese companies have already evinced interest in leveraging the contract manufacturing benefits from the US Food and Drug Administration-approved facilities in India," Dr Appaji said.

The contract manufacturing space in India is expected to gain grounds in the near future and expected to grow by 17%-18% on a compound annual growth rate basis as efficiency in manufacturing and maturity of business models would lead to containment of cost of manufacturing to a great extent.

Source : http://www.thepharmaletter.com/article/pharma-contract-manufacturing-on-the-rise-in-india

Image source : http://qualitron.in/services/contract-manufacturing